We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Omalizumab, an Anti-IgE mAb, Receives Approval for the Treatment of Chronic Idiopathic/Spontaneous Urticaria.
- Authors
Wu, Keith C P; Jabbar-Lopez, Zarif K
- Abstract
Omalizumab, an anti-IgE mAb, has recently been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of chronic idiopathic urticaria. Saini et al. (2014) (this issue) report on ASTERIA I, a 40-week randomized, double-blinded, placebo-controlled phase III trial evaluating omalizumab for the treatment of this disease.
- Subjects
NETTLES; TREATMENT of urticaria; UNITED States. Food &; Drug Administration; EUROPEAN Medicines Agency; RANDOMIZED controlled trials; THERAPEUTICS
- Publication
Journal of Investigative Dermatology, 2015, Vol 135, Issue 1, p13
- ISSN
0022-202X
- Publication type
Article
- DOI
10.1038/jid.2014.362